Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(d) Appointment of Director.
On October 14, 2020, the board of directors (the “Board”) of ReWalk Robotics Ltd. (the “Company,” “we” or “us”) appointed Ms. Randel E. Richner as a Class II Director of the Company, with such
appointment to take effect on November 1, 2020. Ms. Richner was appointed to fill a vacancy on the Board. Ms. Richner has not yet been appointed to any committees of the Board.
Ms. Richner, 65, has over thirty years’ experience in health policy, reimbursement, and economics. From 2013 to 2015, Ms. Richner served as Executive Vice President of Intralign Health, LLC. From
2006 to 2012, she was President and Founder of Neocure Group, data analytics, health economics and reimbursement strategic services, acquired by Intralign Health, LLC, 2013. From 1997 to 2006, Ms. Richner was Vice President of Global Government
Affairs and Reimbursement, Boston Scientific Corporation.
Ms. Richner has engaged with U.S. Congress and CMS, appointed as first industry representative, Executive
Committee (EC) Medicare Coverage Advisory Committee (MCAC). Presently, she is on the
Executive Dean’s Advisory Board, University of Michigan’s School of Public Health, Executive Board MichBio, Chairperson, Diversity Council. Mr. Richner has served
on multiple boards including MassMedic (founding Women in MedTech), Executive
Advisory Board Center for Evaluation Value, Risk Tufts New England Medical Center, International Society of Pharmacoeconomics and Research (ISPOR), founding the U.S.
Medical Device Council. She’s an invited executive lecturer Dartmouth, Tuck School of Business, University of Michigan School of Engineering and School of Public Health. She has a Master of Public Health in Health Policy and
Administration and a Bachelor of Science in Nursing from University of Michigan.
As compensation for her services as director, Ms. Richner will be entitled to standard compensation available to non-employee directors of the Company as disclosed under “Director Compensation” in
the Company’s definitive proxy statement on Schedule 14A, filed with the SEC on May 12, 2020. Additionally, in connection with her appointment, Ms. Richner has entered into the Company’s standard form of indemnification agreement and will receive
coverage under the Company’s directors’ and officers’ liability insurance policy. Other than with respect to the above-described arrangements, there are no transactions in which Ms. Richner has an interest requiring disclosure under Item 404(a) of
Regulation S-K, and Ms. Richner does not have any family relationship with any director or executive officer of the Company or any person nominated or chosen by the Company to become a director or executive officer.